Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

CYP2D6 Genotyping in Patients on Psychoactive Drug Therapy

Elizabeta Topić / Mario Štefanović / Ana Maria Ivanišević / Franciska Blazinić / Jadranka Čulav / Željko Skočilić
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.135

Abstract

The polymorphic isoenzyme CYP2D6 has a major role in the oxidative metabolism of many deal of psychoactive drugs. Its six mutant alleles (null alleles *3, *4, *5, *6, *7 and *8) encode for inactive enzyme molecules. A carrier of two mutant alleles is considered a poor metabolizer phenotype, while a carrier of only one damaged allele is considered an intermediate metabolizer phenotype. The aim of the study was to assess the prevalence of null alleles in a group of psychiatric patients suffering from depression (n=49) and schizophrenia (n=86) in comparison with healthy individuals (n=145) by the method of multiplex allele specific PCR. Only CYP2D6*3,*4 and *6 mutant alleles were found in the study subjects. No significant difference between the depression and control groups was found for allele prevalence, genotype or phenotype distribution (p>0.05). However, a significant difference was observed between schizophrenic patients and controls for allele frequency (p=0.002), genotype distribution (p=0.016), and phenotype prevalence (p=0.018). The odds ratio of 2.542 for 2D6*4 suggested a significant association between this allele and schizophrenia, significantly contributing to poor metabolizer phenotype (odds ratio=5.020). The relationship between CYP2D6 gene polymorphism and side effects in schizophrenic patients undergoing long-term psychoactive drug therapy was investigated. A significant difference was obtained for allele prevalence (p=0.002), genotype (p=0.029), and phenotype (p=0.002) distribution between patients without and with side effects. A relative risk of 2.626 and 5.333 for 2D6*4 and 2D6*6, respectively, and of 7.08 for poor metabolizer phenotype suggested a significant association between the hereditary susceptibility for a particular type of drug metabolism (defect alleles) and side effects. These preliminary r e s u l t s suggest that the CYP2D6 genotyping appears to be useful for predicting risks for side effects of psychoactive drugs in schizophrenic patients, but their usefulness should be further explored.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 921–927, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.135.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Irma Meijerman, Linda M. Sanderson, Paul H.M. Smits, Jos H. Beijnen, and Jan H.M. Schellens
Drug Metabolism Reviews, 2007, Volume 39, Number 1, Page 45
[3]
J C Stingl, J Brockmöller, and R Viviani
Molecular Psychiatry, 2013, Volume 18, Number 3, Page 273
[4]
Chee Hong Ng, Chee Hong Ng, Isaac Schweitzer, Trevor Norman, and Simon Easteal
Australian & New Zealand Journal of Psychiatry, 2004, Volume 38, Number 7, Page 483
[5]
N Fleeman, Y Dundar, R Dickson, A Jorgensen, S Pushpakom, C McLeod, M Pirmohamed, and T Walley
The Pharmacogenomics Journal, 2011, Volume 11, Number 1, Page 1
[6]
Anna Crescenti, Sergi Mas, Patricia Gassó, Eduard Parellada, Miquel Bernardo, and Amalia Lafuente
Clinical and Experimental Pharmacology and Physiology, 2008, Volume 35, Number 7, Page 807
[7]
A Crescenti, S Mas, P Gassó, M Baiget, M Bernardo, and A Lafuente
Clinical and Experimental Pharmacology and Physiology, 2007, Volume 34, Number 10, Page 992
[8]
W-M Cai, D M Nikoloff, R-M Pan, J de Leon, P Fanti, M Fairchild, W H Koch, and P J Wedlund
The Pharmacogenomics Journal, 2006
[9]
Chee Hong Ng, Isaac Schweitzer, Trevor Norman, and Simon Easteal
Australian and New Zealand Journal of Psychiatry, 2004, Volume 38, Number 7, Page 483

Comments (0)

Please log in or register to comment.
Log in